Drug intelligence / Profile preview

89Zr-NY009

Development stage: Phase 1
Lead developer: Telix Pharmaceuticals
Administration: Intravenous

Overview

89Zr-NY009 is a diagnostic imaging agent that uses zirconium-89 (89Zr) as a radioisotope for positron emission tomography (PET) imaging. It is administered intravenously and appears to be in preclinical development, with a single-arm study evaluating its safety and biodistribution in patients. 89Zr has a long half-life of approximately 78.4 hours, making it suitable for imaging applications that require extended observation periods, which is particularly useful for antibody-based imaging agents that have slower biodistribution kinetics.

Other names: 89Zr-labeled NY009

Beyond the preview

Go deeper on 89Zr-NY009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89Zr-NY009.

Explore the full profile